Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Ipamorelin is a synthetic pentapeptide studied as a selective growth hormone secretagogue and ghrelin receptor agonist. In research settings, it is primarily examined for its ability to stimulate growth hormone release through GHSR-related signaling pathways while showing a different endocrine selectivity profile than earlier compounds in the same category. This 2026 guide covers the molecular profile, proposed mechanisms, research areas, comparative analysis, and evidence limitations of Ipamorelin based strictly on peer-reviewed sources.
Ipamorelin is a synthetic pentapeptide (5 amino acids) that acts as a selective growth hormone secretagogue and ghrelin receptor agonist. It is studied for its ability to stimulate GH release from the pituitary through GHSR-1a signaling while showing relatively less ACTH and cortisol stimulation than earlier comparator compounds in published models. Molecular weight: 711.85 g/mol. Formula: C₃₈H₄₉N₉O₅. It is not growth hormone itself and is not FDA-approved.
Ipamorelin is most relevant in research as a signaling compound used to investigate GH-axis biology, endocrine selectivity, and downstream physiological pathways linked to growth hormone release. Early published pharmacology work described it as the first selective growth hormone secretagogue, distinguishing it from earlier GHRPs based on a more targeted hormonal profile in tested models.
Ipamorelin is studied as a peptide that can signal the pituitary to release growth hormone through the ghrelin receptor pathway. It is not growth hormone itself. Researchers are mainly interested in it because early studies suggested a relatively selective GH-releasing profile with less impact on cortisol and ACTH than older secretagogue comparators. The human evidence base is still limited and much of the published work remains preclinical.
Growth hormone secretagogues are often studied as tools for understanding endocrine signaling rather than as broad outcome compounds. Ipamorelin's strongest published rationale centers on GH release, ghrelin receptor activity, and specific downstream physiologic effects that can be measured in controlled laboratory settings.
Ipamorelin has a well-defined chemical identity confirmed across published pharmacology literature and regulatory documentation.
Ipamorelin is studied as a ghrelin mimetic that activates the growth hormone secretagogue receptor (GHSR-1a), triggering pituitary GH release through a pathway distinct from growth hormone releasing hormone (GHRH).
| Mechanism | Research Context | Key Observations |
|---|---|---|
| GHSR-1a Receptor Activation | Pituitary GH release research | Ipamorelin binds the ghrelin receptor (GHSR-1a) and is studied for its ability to stimulate pulsatile GH secretion from the pituitary gland in a dose-dependent manner. |
| Selective Endocrine Profile | Comparative secretagogue research | Early pharmacology work described Ipamorelin as having relatively less stimulation of ACTH and cortisol than some earlier GHRP comparators in tested models, which is one reason it attracted sustained research interest. |
| IGF-1 Downstream Signaling | GH-axis physiology research | GH release prompted by Ipamorelin may increase insulin-like growth factor 1 (IGF-1) levels, a primary downstream mediator of GH activity on tissue signaling and growth-related pathways. |
| Pulsatile GH Secretion Mimicry | Endocrine biology research | Research has examined whether Ipamorelin can enhance the natural pulsatile pattern of GH secretion rather than producing a single large hormonal release, a feature studied in the context of endocrine health modeling. |
| Ghrelin Receptor Pathway in the GI Tract | Gastrointestinal motility research | Ghrelin receptors are also present in the gastrointestinal tract. This has made Ipamorelin relevant in GI motility and postoperative ileus research as a ghrelin mimetic with potential pro-motility activity. |
A growth hormone secretagogue is a compound that stimulates the secretion of growth hormone from the pituitary gland, typically through the ghrelin receptor pathway rather than through GHRH. Ipamorelin belongs to this class and is classified as a synthetic pentapeptide GHS with a selective endocrine profile relative to earlier compounds in the same category.
Ipamorelin is often evaluated alongside other growth hormone secretagogues. The following comparison reflects published pharmacology research and is provided for research reference only.
| Feature | Ipamorelin | GHRP-6 | GHRP-2 | MK-677 (Ibutamoren) |
|---|---|---|---|---|
| Compound type | Synthetic pentapeptide | Synthetic hexapeptide | Synthetic hexapeptide | Non-peptide small molecule |
| GH selectivity | High selectivity in studied models | Moderate selectivity | Moderate selectivity | High selectivity |
| ACTH / Cortisol stimulation | Minimal in published models | Significant stimulation observed | Moderate stimulation observed | Low stimulation observed |
| Appetite stimulation | Low | Very high (ghrelin-like) | High | High |
| Plasma half-life | ~2 hours | ~30 minutes | ~60 minutes | ~24 hours |
| Administration route in studies | Injection (subcutaneous / IV) | Injection | Injection | Oral |
| GI motility research | Yes, studied in postoperative ileus models | Limited | Limited | Not a primary focus |
Ipamorelin has been studied across several experimental and early clinical contexts. The following summarizes the primary research domains represented in the published literature.
| Research Area | Study Context | Nature of Findings |
|---|---|---|
| Growth Hormone Signaling | Endocrine pharmacology and GH-axis research | The primary published use case for Ipamorelin is its ability to stimulate GH release through GHSR-1a. Pharmacology work established its selective profile relative to earlier GHRPs and documented its dose-response characteristics in animal models. |
| Pharmacokinetics and Pharmacodynamics | Human PK/PD infusion studies | Human research has examined how Ipamorelin behaves in the body and how GH levels respond at different infusion rates. This provides controlled human data on receptor-level activity, though it does not establish broad real-world outcome claims. |
| Gastrointestinal Motility | Rodent GI motility models | Animal studies examined Ipamorelin as a ghrelin mimetic in gastric dysmotility models. Findings are mechanistic and limited to preclinical contexts. |
| Postoperative Ileus | Phase 2 proof-of-concept human trial | A prospective, randomized, controlled proof-of-concept study explored whether ghrelin receptor agonism via Ipamorelin could improve postoperative gut function. This is among the more visible human research on the compound but represents an early-stage finding. |
| Bone Formation and Mineral Content | Preclinical bone physiology research | Preclinical studies examined Ipamorelin in relation to bone formation, bone mineral content, and glucocorticoid-related bone loss in animal models. These findings are mechanistically interesting but remain preclinical. |
Proper handling is essential for maintaining Ipamorelin's research-grade integrity from receipt through experimental use.
| Parameter | Detail | Research Significance |
|---|---|---|
| Plasma half-life | Approximately 2 hours | Longer than many older GHRPs, which makes it suitable for protocols examining sustained GH release patterns relative to shorter-acting comparators. |
| Administration route in studies | Subcutaneous or intravenous injection | Published human PK/PD and clinical research has used intravenous infusion. Subcutaneous administration is the more common format in broader preclinical and exploratory research settings. |
| Lyophilized storage | -20°C | Standard lyophilized peptide storage applies. Integrity of the pentapeptide sequence must be preserved before reconstitution. |
| Post-reconstitution storage | 2-8°C | Once reconstituted with bacteriostatic water, keep refrigerated and use within the appropriate research window. Avoid repeated freeze-thaw cycles. |
| Environmental exposure | Avoid heat, light, and moisture | All three accelerate peptide degradation and reduce compound integrity before and after reconstitution. |
Ipamorelin has a growing but still limited human evidence base. Researchers and readers should interpret the literature with the following boundaries clearly in mind.
For a compound where formal regulatory approval is absent and FDA materials have raised characterization concerns in compounding contexts, the quality of the supplied material is especially important. These are the standards that matter most when evaluating any Ipamorelin supplier in Canada or the USA.
| Standard | Why It Matters for Ipamorelin Research |
|---|---|
| Third-party HPLC testing | Independent verification confirms the compound meets research-grade purity standards and removes reliance on supplier-issued data alone. |
| Mass spectrometry identity confirmation | Confirms molecular weight and sequence identity for the pentapeptide. Identity verification is especially important given FDA-noted concerns about characterization of compounded peptides. |
| Batch-specific COA availability | Lot-level traceability allows researchers to document the exact material used and compare results across batches or protocols over time. |
| 99%+ purity threshold | Lower purity introduces uncontrolled impurities into GH-axis and GI motility research models, adding variables that compromise data quality. |
| Research-use-only labeling and positioning | Ensures correct framing as a laboratory material and supports regulatory compliance in both Canada and the USA. |
These pages extend the GH-axis signaling, endocrine research, and Canadian research quality context surrounding Ipamorelin.
These answers cover the most common Ipamorelin research and sourcing questions from researchers in Canada and the USA in 2026.
Ipamorelin is a synthetic pentapeptide studied as a selective growth hormone secretagogue and ghrelin receptor agonist. Molecular weight: 711.85 g/mol. Formula: C₃₈H₄₉N₉O₅. It is not growth hormone itself and is not FDA-approved. It is studied for its ability to activate ghrelin receptor signaling and stimulate GH release from the pituitary.
No. Ipamorelin is not growth hormone. It is a signaling peptide studied for its ability to prompt GH release indirectly through ghrelin receptor activation. Researchers interested in growth hormone itself are working with an entirely different compound.
Ipamorelin is studied as a ghrelin mimetic that binds the GHSR-1a receptor (ghrelin receptor) and stimulates GH secretion from the pituitary. Published pharmacology work described it as having relatively less ACTH and cortisol stimulation than earlier GHRP comparators in tested models, which gave it a more selective profile in the GHS literature.
Published studies have explored GH signaling and endocrine selectivity, pharmacokinetics and pharmacodynamics, gastrointestinal motility, postoperative ileus, and bone-related physiology in preclinical models. Most of the literature is either mechanistic, preclinical, or limited-scope human research.
No. FDA briefing materials state there are no FDA-approved drug products containing Ipamorelin. FDA materials have also noted unresolved issues around safety, formulation, impurities, and route-of-administration considerations in the compounding context. Ipamorelin is positioned strictly as a research-use-only compound.
A large portion of the published literature is preclinical. Human data exist in the form of PK/PD infusion studies and a phase 2 proof-of-concept trial in postoperative ileus, but these are relatively narrow in scope. Broad human outcome evidence across recovery, body composition, or anti-aging applications is not currently available in the literature.
Peptide identity, purity, handling, and documentation matter particularly for a compound where formal regulatory approval is absent and FDA materials have raised safety and characterization concerns in compounding contexts. Researchers should prioritize suppliers with third-party analytical verification, batch-level COA documentation, and consistent storage and handling practices.
All Luxara Labs peptides, including Ipamorelin, are tested to a minimum of 99% purity by independent third-party HPLC and mass spectrometry analysis. A batch-specific Certificate of Analysis (COA) is available for every order. Verification is performed by independent labs before any product is released.
The following peer-reviewed references, regulatory materials, and database records support the content discussed on this page. All links direct to verified primary sources.
Join our list and get an instant 10% discount code — valid for first-time buyers.
